Vivos TherapeuticsVVOS +9.34%41 Beneish M-Score is -2.43 as of Jun. 30, 2026. GuruFocus rates VVOS with a GF Score™ of 41/100 and a GF Value™ of $1.16 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 765 Medical Devices & Instruments companies, Vivos Therapeutics ranks worse than 62.75% on this metric.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Good Sign:
Beneish M-Score -2.43 no higher than -1.78, which implies that the company is unlikely to be a manipulator.
The historical rank and industry rank for Vivos Therapeutics's Beneish M-Score or its related term are showing as below:
VVOS'
s Beneish M-Score Range Over the Past 10 Years
Min: -6.3 Med: -2.83 Max: 0.7
Current: -2.43
During the past 8 years, the highest Beneish M-Score of Vivos Therapeutics was 0.70. The lowest was -6.30. And the median was -2.83.
Vivos Therapeutics Beneish M-Score Related Terms
Vivos Therapeutics Beneish M-Score Historical Data
* Premium members only.
The historical data trend for Vivos Therapeutics's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VVOS vs XAIR, TNON, BMRA: Beneish M-Score Comparison
For the Medical Devices subindustry, Vivos Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivos Therapeutics Beneish M-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vivos Therapeutics's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Vivos Therapeutics's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Vivos Therapeutics for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 1.8418
+
0.528 * 0.9502
+
0.404 * 1.6703
+
0.892 * 1.3377
+
0.115 * 0.7245
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 1.2833
+
4.679 * -0.201653
-
0.327 * 1.768
=
-2.43
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(0.612 / (0.612 + 4.259))
/
(1.586 / (1.586 + 7.559))
=
0.125642
/
0.173428
=
0.7245
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(-25.049 - -2.522
-
-17.477)
/
25.043
=
-0.201653
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Vivos Therapeutics has a M-score of -2.43 suggests that the company is unlikely to be a manipulator.
Vivos Therapeutics (VVOS) has a Beneish M-Score of -2.43 as of Jun. 30, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Vivos Therapeutics and its competitors. According to the industry distribution chart, Vivos Therapeutics ranks #480 out of 765 companies in the Medical Devices & Instruments industry, placing it in the top 62.7%.
Is Vivos Therapeutics' Beneish M-Score too high?
Vivos Therapeutics' current Beneish M-Score is -2.43. Based on the distribution chart, Vivos Therapeutics ranks #480 out of 765 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Vivos Therapeutics has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vivos Therapeutics' Beneish M-Score compare to XAIR and TNON?
According to the Medical Devices & Instruments industry distribution chart, Vivos Therapeutics ranks #480 out of 765 companies for Beneish M-Score. This places Vivos Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Vivos Therapeutics and its competitors. Vivos Therapeutics's current Beneish M-Score is -2.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Vivos Therapeutics (VVOS) is currently considered Possible Value Trap. The stock's GF Value™ is $1.16, compared to a current price of $0.49 — trading 57.5% below its estimated fair value. The current Beneish M-Score is -2.43. Vivos Therapeutics' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Vivos Therapeutics (VVOS), the current Beneish M-Score is -2.43 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vivos Therapeutics (VVOS) Overvalued in 2026?
Based on GuruFocus' analysis, Vivos Therapeutics stock appears to be undervalued.
The current stock price of $0.49 is trading 57.5% below its estimated GF Value™ of $1.16.
GuruFocus considers Vivos Therapeutics to be Possible Value Trap.
Key valuation signals for VVOS:
Beneish M-Score: -2.43
GF Value™: $1.16 vs. price of $0.49 (57.5% below fair value)
No single metric tells the full story. See the VVOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
41GF Score
Get the complete analysis for VVOS
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VVOS has been successfully added to your 
